Sabatolimab is a humanized monoclonal antibody directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Sabatolimab has been approved for the treatment of adult patients with myelodysplastic syndromes (MDS).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.